1·No long-term toxicity potentially due to rituximab was observed.
未见利妥昔单抗的长期潜在毒性。
2·Rituximab may be effective for the treatment of CD20-positive MM.
美罗华可有效地用于治疗抗cd 20阳性毫米。
3·There was no increase in infections or neutropenia with rituximab.
感染和中性粒细胞减少症都没有增加。
4·Rituximab may be effective in controlling MCD in a subset of patients.
美罗华可有效地控制麦当劳中的一个子集的患者。
5·But this was the luck of the draw, for the rituximab failed to kill the cancer stem cells.
但这也许只是运气，因为rituximab没能杀灭干细胞。
6·Patients get rituximab through infusion into a vein (IV) at the oncologist's office or clinic.
患者可在肿瘤专家的办公室或门诊接受静脉注入美罗华。
7·Conclusion: Combination treatment of rituximab and CHOP is effective and of little side effect.
结论：利妥昔单抗联合CHOP方案治疗DLBCL，疗效好，不良反应小。
8·Addition of GM-CSF did not impair tolerance to rituximab, and adverse events were rare and mild.
添加GM-CSF不减弱美罗华的耐受性，不良反应很少，并且很轻。
9·In the study that led to the FDA approval, most patients were refectory to bendamustine and rituximab.
在向FDA申报批准的临床研究中，大部分病人都对苯达莫司汀和利妥昔单抗耐药。
10·We report successful treatment with plasmapheresis and rituximab in NMO-IgG-negative relapsing disease.
我们成功的治疗报告，并与血浆中的美罗华吗啉抗体阴性复发疾病。
1·Treatment with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked reduction in antibody levels and relapse rates.
免疫抑制剂治疗，如利妥昔单抗，硫唑嘌呤和环磷酰胺，明显减少抗体水平和复发率。
2·More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.
更多的利妥昔单抗组的患者在第一次注射后发生不良反应，大多数都是1或2级的。
3·Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.
怀孕前应终止使用的药物包括甲氨蝶呤、来氟米特和一些生物制剂包括抗肿瘤坏死因子制剂、利妥昔单抗和阿巴西普。
4·In the study that led to the FDA approval, most patients were refectory to bendamustine and rituximab.
在向FDA申报批准的临床研究中，大部分病人都对苯达莫司汀和利妥昔单抗耐药。
5·Of previously untreated patients receiving prolonged treatment after responding to rituximab induction, at 8 years 45% were still without event.
先前未经治疗、而对利妥昔单抗诱导缓解有效后接受延长治疗的患者中，8年有45%患者仍无事件发生。
1·Patients get rituximab through infusion into a vein (IV) at the oncologist's office or clinic.
患者可在肿瘤专家的办公室或门诊接受静脉注入美罗华。
2·Rituximab specifically recognizes and attaches to a protein called CD20 that is found on the surface of some lymphocytes.
美罗华特异的识别和附着于在一些淋巴细胞表面可以找到蛋白cd 20。
3·Rituximab may be effective in controlling MCD in a subset of patients.
美罗华可有效地控制麦当劳中的一个子集的患者。
4·We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.
我们观察到的恶化伴随皮肤卡波西氏肉瘤，并推测这种美罗华可能加剧。
5·Addition of GM-CSF did not impair tolerance to rituximab, and adverse events were rare and mild.
添加GM-CSF不减弱美罗华的耐受性，不良反应很少，并且很轻。